1. Home
  2. SLRX vs PSTV Comparison

SLRX vs PSTV Comparison

Compare SLRX & PSTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLRX
  • PSTV
  • Stock Information
  • Founded
  • SLRX N/A
  • PSTV 1996
  • Country
  • SLRX United States
  • PSTV United States
  • Employees
  • SLRX N/A
  • PSTV N/A
  • Industry
  • SLRX Biotechnology: Pharmaceutical Preparations
  • PSTV Medical/Dental Instruments
  • Sector
  • SLRX Health Care
  • PSTV Health Care
  • Exchange
  • SLRX Nasdaq
  • PSTV Nasdaq
  • Market Cap
  • SLRX N/A
  • PSTV 2.1M
  • IPO Year
  • SLRX N/A
  • PSTV N/A
  • Fundamental
  • Price
  • SLRX $0.73
  • PSTV $0.79
  • Analyst Decision
  • SLRX
  • PSTV Strong Buy
  • Analyst Count
  • SLRX 0
  • PSTV 3
  • Target Price
  • SLRX N/A
  • PSTV $11.50
  • AVG Volume (30 Days)
  • SLRX 257.2K
  • PSTV 3.8M
  • Earning Date
  • SLRX 05-12-2025
  • PSTV 05-14-2025
  • Dividend Yield
  • SLRX N/A
  • PSTV N/A
  • EPS Growth
  • SLRX N/A
  • PSTV N/A
  • EPS
  • SLRX N/A
  • PSTV N/A
  • Revenue
  • SLRX N/A
  • PSTV $5,824,000.00
  • Revenue This Year
  • SLRX N/A
  • PSTV $13.26
  • Revenue Next Year
  • SLRX N/A
  • PSTV $24.59
  • P/E Ratio
  • SLRX N/A
  • PSTV N/A
  • Revenue Growth
  • SLRX N/A
  • PSTV 18.54
  • 52 Week Low
  • SLRX $0.45
  • PSTV $0.24
  • 52 Week High
  • SLRX $7.20
  • PSTV $2.67
  • Technical
  • Relative Strength Index (RSI)
  • SLRX 44.60
  • PSTV 47.37
  • Support Level
  • SLRX $0.61
  • PSTV $0.61
  • Resistance Level
  • SLRX $0.75
  • PSTV $1.22
  • Average True Range (ATR)
  • SLRX 0.09
  • PSTV 0.13
  • MACD
  • SLRX 0.03
  • PSTV 0.02
  • Stochastic Oscillator
  • SLRX 70.53
  • PSTV 29.16

About PSTV PLUS THERAPEUTICS Inc.

Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).

Share on Social Networks: